AML1/Evi-1 is a chimeric protein that is derived from t(3;21), found in blastic transformation of chronic myelogenous leukemia. It is composed of the N-terminal AML1 portion with the DNA-binding Runt domain and the C-terminal Evi-1 portion. It has been shown to dominantly repress AML1-induced transactivation. The mechanism for it has been mainly attributed to competition with AML1 for the DNA-binding and for the interaction with PEBP2b (CBFb), a partner protein which heterodimerizes with AML1. It was recently found that Evi-1 interacts with C-terminal binding protein (CtBP) to repress TGFb-induced transactivation. Here, we demonstrate that AML1/Evi-1 interacts with CtBP in SKH1 cells, a leukemic cell line which endogenously overexpresses AML1/Evi-1 and that AML1/Evi-1 requires the interaction with CtBP to repress AML1-induced transactivation. The association with CtBP is also required when AML1/Evi-1 blocks myeloid dierentiation of 32Dcl3 cells induced by granulocyte colonystimulating factor. Taken together, it is suggested that one of the mechanisms for AML1/Evi-1-associated leukemogenesis should be an aberrant recruitment of a corepressor complex by the chimeric protein.
Introduction
The AML1 gene, which is located in human chromosome 21q22, was originally identi®ed in the cells of acute myelogenous leukemia with t(8;21) (Miyoshi et al., 1991) . The AML1 protein (also called as PEBP2aB, CBFA2, or Runx1) is a member of the AML1 transcription factor family, which is also called as polyomavirus enhancer binding protein 2 (PEBP2), core binding factor (CBF) or most recently, Runx (Wheeler et al., 2000) . Runx proteins share the Runt domain, which has homology to a Drosophila protein, runt. Through this domain, Runx proteins heterodimerize with a b subunit, PEBP2b (CBFb), which is common to each Runx family member. The heterodimers bind to the cognate sequence of DNA, which is called the PEBP2-binding site, in the regulatory region of target genes. This protein-DNA interaction is also mediated through the Runt domain. Three members of this family have been identi®ed to date, each of which is reported to have a unique role in embryogenesis and development. AML1-null mice are not able to establish adult type hematopoiesis, and succumb to intracranial hemorrhage around embryonic day 12.5 (Okuda et al., 1996) . Thus, AML1 seems to be essential for establishing the hematopoietic system during embryonic ontogeny . It remains to be elucidated precisely what are the downstream targets of AML1 during induction of adult type hematopoiesis. Several hematopoietic lineage-speci®c genes, however, are shown to be regulated by AML1. Among them are the genes for myeloperoxidase (MPO), neutrophil elastase, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor, macrophage colony-stimulating factor (M-CSF) receptor, and T-cell receptor b.
On the other hand, alterations in the AML1 gene closely associate with the development of hematological disorders in humans. The AML1 gene is recurrently involved in leukemia-associated chromosomal translocations (Mitani, 1997) . The translocations generate fusion transcripts and the resulting chimeric proteins that consist of AML1 and a product from each partner gene. AML1/Evi-1, AML1/ETO(MTG8), and TEL/ AML1 chimeric proteins are generated by t(3;21), t(8;21), and t(12;21), respectively (Golub et al., 1995; Mitani et al., 1994; Miyoshi et al., 1993) . Germ line mutations in the AML1 gene are reported in the pedigrees of familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) (Song et al., 1999) . Somatic mutations in AML1 have been repeatedly found in cases of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) (Imai et al., 2000; Osato et al., 1999) . These mutations result in either loss of one AML1 allele that leads to decrease in the product, or generation of a mutant AML1 protein that dominantly inhibits the function of the normal AML1 protein. Thus, alterations in the AML1 gene product are closely associated with human leukemias.
Previously, we cloned the AML1/Evi-1 fusion gene from a case with blastic crisis of chronic myelogenous leukemia (CML) causing the t(3;21) translocation . The AML1/Evi-1 gene encodes a fusion protein consisting of the N-terminal portion of AML1, including the Runt domain, fused in frame to the complete Evi-1 protein. The Evi-1 gene is located in human chromosome 3q26, and encodes a transcriptional regulator protein with two zinc ®nger domains. The Evi-1 protein itself is expressed aberrantly in leukemic cells, and is suggested to have close association with the pathogenesis of myelogenous leukemia (Hirai, 1999; Kurokawa et al., 1998b Kurokawa et al., , 2000 . The biological eect of the AML1/Evi-1 chimeric protein in cells has been studied so far. It was shown to exhibit transforming activity on Rat1 ®broblasts (Kurokawa et al., 1995) . In hematopoietic cells, it blocks granulocytic dierentiation of the 32Dcl3 cell line when stimulated with granulocyte colony-stimulating factor (G-CSF) (Tanaka et al., 1995a) . Furthermore, using a retroviral transduction and transplantation approach, the expression of AML1/ Evi-1 in bone marrow cells was shown to induce acute myelogenous leukemia in mice (Cuenco et al., 2000) . Taken together, AML1/Evi-1 should have a distinct role in leukemogenesis. Several mechanisms by which the expression of AML1/Evi-1 in hematopoietic cells leads to leukemias have been proposed to date. AML1/ Evi-1 raises AP-1 activity presumably through elevating the expression of c-jun and c-fos (Tanaka et al., 1995a) . It interacts with Smad3 and interrupts TGFbinduced signal transduction (Kurokawa et al., 1998a) . Moreover, AML1/Evi-1 dominantly inhibits AML1-induced transactivation, which was shown to result from a competitive inhibition. AML1/Evi-1 can interact with PEBP2b subunit more eectively than AML1 does (Tanaka et al., 1998) . In addition, the AML1/Evi-1-PEBP2b heterodimer has advantage in interacting with the PEBP2-binding site compared with the AML1-PEBP2b heterodimer (Tanaka et al., 1995a) . Recently, we showed that C-terminal binding protein (CtBP) interacts with Evi-1 to repress TGFb-induced transcription (Izutsu et al., 2001) . CtBP was originally identi®ed as a protein which interacts with a Cterminal portion of adenovirus E1A protein (Boyd et al., 1993; Turner and Crossley, 2001) . To date, two highly related proteins, termed CtBP1 and CtBP2, have been reported both in mice and humans (Turner and Crossley, 2001) . The dierence in function between these proteins remains to be elucidated, although their expression pattern in the embryonic and adult tissue has been reported to be slightly dierent from each other (Katsanis and Fisher, 1998) . They have been recognized as corepressor proteins which mediate repression by associating with several transcription factors including basic KruÈ ppel-like factor (BKLF) (Turner and Crossley, 1998) , friend of GATA (FOG) (Fox et al., 1999) , and T-cell factor (TCF) (Brannon et al., 1999) . Although it is not precisely elucidated how CtBP mediates transcriptional repression, it is supposed that histone deacetylase 1 (HDAc1), which was demonstrated to interact with CtBP, may be involved in repression (Sundqvist et al., 1998) . Recent studies showed that AML1/ETO(MTG8), a fusion protein which is derived from t(8;21), represses the AML1-driven promoter through the interaction with corepressor proteins: it directly interacts with a mammalian homolog of yeast transcriptional repressor SIN (mSin3) A and nuclear hormone corepressor (NCoR), thereby recruiting HDAc1 (Lutterbach et al., 1998; Wang et al., 1998) . Therefore, it is assumed that aberrant recruitment of a corepressor complex to AML1 target genes may have a pivotal role in AML1/ETO(MTG8)-associated leukemogenesis. As for AML1/Evi-1, however, a role for corepressor proteins has not been de®ned to date. Then, we hypothesized that transcriptional repression by AML1/Evi-1 might be attributed to interaction with a corepressor complex including CtBP.
In this study, we found that AML1/Evi-1 endogenously interacts with CtBP and that the interaction with it may be responsible for transcriptional repression and block in myeloid dierentiation by AML1/Evi-1.
Results

AML1/Evi-1 interacts with CtBP
To investigate a potential role of CtBP in AML1/Evi-1-mediated transcriptional repression, we ®rst examined whether AML1/Evi-1 interacts with CtBP. For this purpose, we performed a coprecipitation experiment by overexpressing T7-tagged CtBP1 (T7-CtBP1) and AML1/Evi-1 in COS7 cells. Whole cell lysates were immunoprecipitated with the anti-T7 antibody and the immunoprecipitates were analysed by immunoblotting with the anti-Evi-1 antibody. As shown in Figure 1a , lane 3, AML1/Evi-1 and CtBP were coprecipitated, which indicates the interaction between AML1/Evi-1 and CtBP in vivo. We previously determined that Evi-1 interacts with CtBP exclusively through one of the two potential CtBP-binding amino acid sequences, PFDLT and PLDLS (Izutsu et al., 2001) . AML1/Evi-1 also retains those two sequences. To determine relative contribution of them to the CtBP binding, we constructed amino acid-substituted mutants for these sequences (Figure 2 ), and tested their ability to interact with CtBP. In AE(AS/DL) mutant, the amino acid sequence, PFDLT in AML1/Evi-1 (AE) is replaced to PFAST. Likewise, PLDLS is replaced to PLASS in AE(DL/AS), and both of PFDLT and PLDLS are to PFAST and PLASS in AE(AS/AS). AED544-607 is a deletion mutant for AML1/Evi-1 in which the region corresponding to amino acids between 544 and 607 of Evi-1 is deleted ( Figure 2 ).
As shown in Figure 1a , AE(AS/DL) was coprecipitated with CtBP, whereas AE(DL/AS), AE(AS/AS), or AED544-607 did not. These results indicate that the PLDLS motif is essential for the interaction between AML1/Evi-1 and CtBP, as is also the case with Evi-1.
The association between AML1/Evi-1 and CtBP was also revealed in SKH1 cells derived from megakaryoblastic crisis of chronic myelogenous leukemia, which endogenously overexpress AML1/Evi-1 . Total cell lysates from SKH1 cells were subjected to immunoprecipitation experiments using the anti-Evi-1 serum. Figure 1b shows that endogenous CtBP1 is coimmunoprecipitated with endogenous AML1/Evi-1. We tested the involvement of CtBP2 by the similar experiment using anti-CtBP2. However, endogenous expression of CtBP2 in SKH1 cells was very faint on the Western blot, and it was barely detected in the immunoprecipitates with anti-Evi-1 (data not shown). Thus, AML1/Evi-1 may form a complex predominantly with CtBP1 at least in SKH1 cells.
Interaction with CtBP is required for the repression of AML1-dependent transactivation
We previously showed that AML1/Evi-1 dominantly represses the AML1-induced transactivation by competing with AML1 for binding to PEBP2b subunit and to DNA (Tanaka et al., 1995a) . AML1/ETO(MTG8), another dominant negative inhibitor for AML1 (Miyoshi et al., 1993) , was shown to recruit a corepressor complex to repress the induction of AML1 target genes (Lutterbach et al., 1998; Wang et al., 1998) . However, contribution of corepressor proteins to AML1/Evi-1-mediated repression has not been elucidated. Given that AML1/Evi-1 interacts with CtBP, we made a hypothesis that AML1/Evi-1-mediated repression might depend on the interaction with CtBP. To investigate this, we used the AML1/Evi-1 mutants, which do not interact with CtBP, and tested their ability to repress AML1-induced transactivation. In this study, we used a reporter plasmid that is driven by the M-CSF receptor promoter (pM-CSF-R-luc) (Zhang et al., 1994) . The reporter plasmid was transfected into HeLa cells along with the plasmids expressing AML1b, one of the major isoform of AML1 in hematopoietic cells (Miyoshi et al., 1995) , and PEBP2b together with those for AML1/Evi-1 or its mutants. Endogenous CtBP1 is expressed in HeLa cells as detected by Western blotting (Figure 3a , lane 1). Coexpression of AML1 and PEBP2b in the cells raised the expression level of the reporter gene about six to eight times as assessed by the luciferase assay. AML1/ Evi-1 suppressed the transactivation elicited by AML1 ) with the pRc/CMV empty vector (lanes 1 and 2) or T7-CtBP1 in pRc/CMV (lanes 3 to 8). Cells were lysed and subjected to immunoprecipitation (IP) with anti-T7. Immunoprecipitates were subjected to Western blot analysis using anti-Evi-1 (top). Positions of size markers in kilodaltons (kDa) are indicated on the left. Expression of AML1/Evi-1 and T7-CtBP1 was monitored with anti-Evi-1 (middle) and anti-T7 (bottom), respectively. (b) SKH1 cells were lysed and subjected to immunoprecipitation with preimmune serum (lane 1) or antiEvi-1 (lane 2). Immunoprecipitates (IP) were subjected to Western blot analysis using anti-CtBP1 (top) and anti-Evi-1 (bottom). Expression of endogenous CtBP1 in SKH1 was determined with anti-CtBP1 (lane 3) Figure 2 Structures of AML1/Evi-1 and its derivative forms. AML1/Evi-1 and its derivative forms are schematically shown. Amino acid substitutions in AE(AS/DL), AE(DL/AS), and AE(AS/AS) are depicted with underlines. In AED544-607, the region between amino acids 544 and 607 of Evi-1 is deleted
Oncogene Dominant negative inhibition on AML1 by AML1/Evi-1 and CtBP K Izutsu et al and PEBP2b (Figure 3b ), as previously described (Zent et al., 1996) . As shown in Figure 3c , AE(AS/DL), which interacts with CtBP, showed the equivalent repression activity. However, the repression activity of AE(DL/AS), AE(AS/AS), or AED(544-607), which does not associate with CtBP, was reduced to about 50% or less (Figure 3c ). These results suggest that AML1/Evi-1 interacts with endogenous CtBP1 and represses the transcription.
Next, in order to assess the role of CtBP directly, we tested the eect of overexpression of CtBP1 on the repression by AML1/Evi-1. As shown in Figure 3d , overexpression of CtBP1 accentuated the repression by AML1/Evi-1. Overexpression of CtBP1, however, did not aect the repression by AE(DL/AS) that was reduced to about 50% of that by AML1/Evi-1 as mentioned earlier (Figure 3c,d ). Taken together, it is indicated that the interaction with CtBP is required for AML1/Evi-1 to fully repress the AML1-induced transactivation.
A role of HDAc in AML1/Evi-1-mediated repression Although a full picture of CtBP-mediated transcriptional repression remains elusive, it is supposed that CtBP mediates repression by interacting with HDAc (Sundqvist et al., 1998; Turner and Crossley, 2001) . Several HDAc proteins have been described in mammalian cells to date. They include class I (HDAc1, HDAc2, HDAc3, and HDAc8), class II (HDAc4, HDAc5, HDAc6, and HDAc7), and several class III HDAc proteins, whose characters are described extensively in the recent review (Khochbin et al., 2001) . Among them, Sundqvist et al. (1998) previously demonstrated that HDAc1 physically interacts with CtBP1 in vivo and in vitro. We also performed an immunoprecipitation experiment and con®rmed the interaction between CtBP1 and HDAc1 in vivo ( Figure  4a ). Next, to investigate a potential role of HDAc in AML1/Evi-1-mediated transcriptional repression, we performed the reporter assay in the presence of histone deacetylase inhibitor, trichostatin A (TSA). For this study, we used another cell line, HepG2 cells, which readily express endogenous CtBP1 (Figure 3a , lane 2), 1 and 3) or T7-CtBP1 in pRc/CMV (lanes 2 and 4) and the pBJ5 empty vector (lanes 1 and 2) or Flag-HDAc1 in pBJ5 (lanes 3 and 4) were cotransfected into COS7 cells (2610 6 ). Cells were lysed and subjected to immunoprecipitation (IP) with anti-Flag. The immunoprecipitates were subjected to Western blotting using anti-T7 (top). Positions of size markers in kilodaltons (kDa) are indicated on the left. Expression of T7-CtBP1 and Flag-HDAc1 was monitored with anti-T7 (middle) and anti-Flag (bottom), respectively. (b) The pM-CSF-R-luc, AML1b, PEBP2b, and C/EBPa were transfected into HepG2 cells together with AML1/Evi-1 or AE(DL/AS) as indicated. Luciferase activities were measured 30 ± 40 h after transfection following an 8-h treatment with or without 50 ng/ml trichostatin A. Bars represent luciferase activities relative to the basal activity of the reporter. Values and error bars depict the mean and the s.d., respectively Dominant negative inhibition on AML1 by AML1/Evi-1 and CtBP K Izutsu et al as the viability of HeLa cells was reduced considerably after the treatment with low concentrations of TSA. In HepG2 cells, basal transcription levels of pM-CSF-Rluc were not aected by the treatment with TSA (data not shown). In addition, the transactivation induced by AML1, PEBP2b, and C/EBPa did not change in the presence or absence of TSA (Figure 4b) . However, the level of repression, which was observed when we overexpressed AML1/Evi-1 in addition to these transactivators, was considerably alleviated by the treatment with TSA (Figure 4b ). In contrast, AE(DL/ AS) mutant that does not interact with CtBP was barely aected by TSA (Figure 4b ). These ®ndings support a model in which AML1/Evi-1 functions as a repressor in concert with a CtBP-HDAc complex.
AML1/Evi-1 inhibits granulocytic differentiation in a CtBP-dependent manner
We previously reported the eect of the AML1/Evi-1 chimeric protein when expressed in 32Dcl3 cells, a murine IL-3-dependent myeloid cell line (Tanaka et al., 1995a) . The 32Dcl3 cells dierentiate into mature granulocytes when treated with G-CSF. The 32Dcl3 cells stably expressing AML1/Evi-1 show block in dierentiation into mature granulocytes in the presence of G-CSF. Given that CtBP is readily detected in 32Dcl3 cells (Figure 3a , lane 3), CtBP would be potentially implicated in AML1/Evi-1-induced eect on 32Dcl3 cells. For the purpose of investigating the eect of CtBP on AML1/Evi-1-mediated dierentiation block, 32Dcl3 cells were transfected with pCXN2-AML1/Evi-1 or pCXN2-AE(DL/AS), in which the expression of AML1/Evi-1 or AE(DL/AS) is driven by the b-actin promoter (Niwa et al., 1991) . Subsequently, the cells were selected for G418 resistance and cloned with limiting dilution. A19 and A23 are representative clones which express AML1/Evi-1, whereas B15 and B56 are clones expressing AE(DL/AS) (Figure 5a ). M1 and M3 are control clones that were transfected with the empty vector. Again, expression of CtBP1 was determined with anti-CtBP1 in each stable clone, and comparable levels of expression were observed (data not shown). When M1, M3, and parental 32Dcl3 cells were cultured with G-CSF instead of IL-3 for several days, the cells dierentiated to mature granulocytes that are characterized by cytoplasmic granules and a segmented or circular nucleus (Figure 5b,c) . In these G-CSF-treated cells, robust induction of mRNA for MPO was observed by Northern blot analyses ( Figure  6 ). In A19 and A23, which overexpress AML1/Evi-1, immature morphological features characterized by a large un-segmented nucleus were maintained in the presence of G-CSF (Figure 5b,c) . Consistently, mRNA for MPO was induced poorly, if any, in A19 and A23 ( Figure 6 ). Thus, overexpression of AML1/Evi-1 blocks G-CSF-induced dierentiation to mature granulocytes of 32Dcl3 cells. On the contrary, in B15 and B56 which carry AE(DL/AS), a mutant form of AML1/Evi-1 defective in interaction with CtBP, morphological features and induction of MPO mRNA were almost similar to those of mock clones in the presence of G-CSF. These results suggest that AML1/ Evi-1 blocks G-CSF-induced granulocytic maturation with dependence on the interaction with CtBP. Taken together, CtBP-dependent repression of AML1 target gene transcription should be one of the mechanisms for AML1/Evi-1-mediated block in granulocytic dierentiation.
Discussion
The transcription factor AML1 plays an essential role in regulating growth and dierentiation of hematopoietic cells. AML1 has been shown to induce the expression of genes which are essential for development . M-CSF induces myelocytic or monocytic dierentiation of hematopoietic cells, so that decreased expression of its receptor would confer refractoriness to dierentiation stimuli in the leukemic cells (Fixe and Praloran, 1998) . Besides M-CSF receptor, it is reasonable to assume that the AML1/Evi-1 represses expression of various AML1 target genes, which are critical for dierentiation of the hematopoietic system, but have not been identi®ed yet. The mechanism of transcriptional regulation by AML1 has been rigorously studied so far. It was shown that AML1 associates with a coactivator complex including p300/CBP, and this association is required for the AML1-induced transactivation (Kitabayashi et al., 1998) . AML1/ETO(MTG8) not only loses p300/CBP-interacting portion of AML1, but also associates with a corepressor complex which contains N-CoR, mSin3A, and HDAc1 via the ETO(MTG8) portion (Lutterbach et al., 1998; Wang et al., 1998) . TEL/AML1 was also shown to interact with a corepressor complex through the TEL portion (Fenrick et al., 1999; Guidez et al., 2000) . These studies indicate that AML1/ETO(MTG8) and TEL/AML1 are not only a competitor for AML1, but also behave as an active repressor for transcription.
In this study, we demonstrate that AML1/Evi-1 physically interacts with CtBP and its association is required for AML1/Evi-1 to fully repress AML1-induced transactivation. CtBP is a distinctive type of corepressor protein, whose mechanisms for repression remain to be fully elucidated. Several transcriptional repressor proteins including FOG (Fox et al., 1999) , TCF (Brannon et al., 1999) , and Net (Criqui-Filipe et al., 1999) have been reported to require CtBP as a corepressor. CtBP was shown to interact with HDAc1 in vivo (Sundqvist et al., 1998) , and some of these transcription factors are susceptible to TSA (CriquiFilipe et al., 1999) . Recently, CtBP was also reported to interact with class II HDAc proteins (Dressel et al., 2001; Zhang et al., 2001) . It is assumed that class I and class II HDAc form a complex to repress transcription whose constituents dier according to genes to be regulated (Khochbin et al., 2001) . Taken together, the CtBP-HDAc complex might be responsible for the transcriptional repression by these transcription factors. The repression by AML1/Evi-1, as we demonstrate here, is also sensitive to TSA, suggesting the involvement of the CtBP-HDAc complex.
An overwhelming majority of the studies on transcriptional regulation has been carried out with experiments using transiently transfected reporters. They have led to the current concept whereby histone acetyl transferases (HAT) and HDAc may play important roles in transcriptional regulation Zhang et al., 1997) . Derepression by HDAc inhibitors has also been demonstrated and tested using these experiments . However, there seems to be concerns about authenticity of these experiments because these reporter constructs may lack nucleosome structures. Some studies including that by Jin and Scotto, (1998) addressed these concerns. They demonstrated that the HDAc inhibitor led to derepression of both the transiently and the stably transfected MDR1 promoter assessed by reporter assays, and that these results corresponded well with those from the Northern blot analyses which showed the induction of the intrinsic MDR1 gene expression by the HDAc inhibitor. Another report also supports these observations (Nagy et al., 1997) . Although the underlying mechanisms remain to be fully elucidated, acetylation and deacetylation of non-histone proteins including basal transcription factors, which have been recently reported, may contribute to these results (Burke and Baniahmad, 2000; Imhof et al., 1997) . The acetylation status of these proteins, which is potentially regulated by HAT and HDAc mutually, may aect transcriptional initiation from transfected reporter constructs as well as from intrinsic promoters. Thus, we believe that experiments using transiently transfected reporters, as in this study, provide a good model for assessing transcriptional regulation by HAT and HDAc and for assessing the eect of HDAc inhibitors.
Provided that the complex consisted from AML1/ Evi-1, CtBP, and HDAc blocks granulocytic dierentiation in 32Dcl3 cells, it is tempting to speculate that HDAc inhibitors would alleviate the block in dierentiation. However, the 32Dcl3 cells cultured in Figure 6 Northern analysis showing expression of the MPO transcript in 32Dcl3 clones. The 32Dcl3 clones were exposed to G-CSF for the indicated periods. Subsequently, total RNAs were prepared from these cells. Aliquots of total RNAs (15 mg per lane) were electrophoresed, transferred to a nylon membrane, and hybridized with a murine myeloperoxidase (MPO) cDNA (top). As a control for RNA loading, the membrane was also hybridized with a mouse glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) cDNA (bottom) Dominant negative inhibition on AML1 by AML1/Evi-1 and CtBP K Izutsu et al the medium containing G-CSF, irrespective of parental cells, mock clones, or AML1/Evi-1-transfected clones, lost viability and died completely within 72 h showing morphological evidence of apoptosis in the presence of 5 ng/ml or above TSA (data not shown). Previous studies show that TSA ranging from 5 to 50 ng/ml or above is required for assessing its in vivo eect in hematopoietic cells (Ferrara et al., 2001; Kosugi et al., 1999) . At lower concentrations, TSA did not aect the G-CSF-induced dierentiation of either 32Dcl3 clone (data not shown). Generally, the HDAc inhibitors including TSA are known to induce growth arrest and apoptosis of cells (Marks et al., 2000) . Reportedly, one of the mechanisms is inducing the expression of p21 WAF1/Cip1 through the HDAc inhibitor activity (Sowa et al., 1999) . The 32Dcl3 cells may be vulnerable to these cytotoxic activities of TSA, so that we could not evaluate its eect on AML1/Evi-1-dependent dierentiation block in this system. We suppose that the threshold of TSA to release the transcriptional repression mediated through AML1/Evi-1 might be higher than that to induce apoptotic cellular response, at least in 32Dcl3 cells. Nevertheless, it is tempting to assess a potential value of HDAc inhibitors in the therapy for AML1-associated leukemias, including AML1/Evi-1-induced leukemia Wang et al., 1999) .
Our study, which suggests an important role of CtBP in AML1/Evi-1-mediated transcriptional repression and inhibition of granulocytic dierentiation, strengthen the recent ®nding that aberrant recruitment of a corepressor complex to AML1 target genes might play a central role in leukemogenesis (Lutterbach et al., 1998; Wang et al., 1998) .
Materials and methods
Cell culture and establishment of stable clones COS7, HeLa, and HepG2 cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with penicillin, streptomycin, and 10% fetal calf serum (FCS) at 378C in a 5% CO 2 incubator. SKH1 cells were maintained in RPMI 1640 with 10% FCS. 32Dcl3 cells were maintained in RPMI 1640 medium supplemented with 0.25 ng of murine interleukin-3 (IL-3) per ml and 10% FCS.
Plasmids
The pME18S-AML1/Evi-1, in which the AML1/Evi-1 complementary DNA (cDNA) was inserted into the EcoRI site of the pME18S vector, was used for transient transfection (Takebe et al., 1988; Tanaka et al., 1995a) . The deletion mutant, pME18S-AED544-607 was constructed substituting the 2.3 kb ApaI-PmaCI fragment of pME18S-AML1/Evi-1 with that of pME18S-Evi-1D544-607 (Izutsu et al., 2001) . Other mutant forms of AML1/Evi-1, AE(DL/AS), AE(AS/ DL), and AE(AS/AS), were generated in the same manner using the corresponding mutants of Evi-1 (Izutsu et al., 2001) . The AML1 and PEBP2b cDNAs were inserted into the EcoRI site of pME18S (Tanaka et al., 1995a,b) .
Transcriptional response assay
Transcriptional response assays were performed with HeLa cells as described previously with minor modi®cations (Imai et al., 2000) . Brie¯y, the cells were seeded in 12-well plate at 4610 4 cells per well. For each well, 1 mg of the reporter and typically 500 ng of the eector plasmid were transfected. As a control of transfection eciency, a plasmid expressing bgalactosidase was cotransfected, and the data were normalized to the b-galactosidase activity. For the experiment using the HDAc inhibitor, HepG2 cells were seeded in 12-well plate at 4610 4 cells per well, and were transfected using SuperFect (Qiagen). The cells were incubated for 30 to 35 h after the transfection and were treated with 50 ng/ml trichostatin A (Waco) for 8 h before harvesting.
Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting were performed as described previously (Izutsu et al., 2001) . For the immunoprecipitation analysis using SKH1 cells, they were lysed in the TNE buer (Kurokawa et al., 1998b) . Lysates were incubated with anti-Evi-1 or with preimmune rabbit serum for 6 h at 48C. Then the samples were incubated with protein-A-Sepharose (Sigma) for 6 h at 48C. The precipitates were washed ®ve times with the TNE buer, and were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS ± PAGE) and analysis by Western blotting. Immunoblotting was performed with anti-CtBP1 or anti-CtBP2 (Santa Cruz Biotechnology) using the enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech). The anti-Flag M2 antibody (Sigma) was used for immunoprecipitation of Flag-tagged HDAc1.
Establishment of 32Dcl3 stable transfectants and granulocytic differentiation assay
To generate stable clones of 32Dcl3 overexpressing AML1/ Evi-1 and its mutant, the constructs subcloned into pCXN2 vector (Niwa et al., 1991) , which has neomycin resistance gene, were transfected by the electroporation method as described previously (Tanaka et al., 1995b) . These cells were selected in medium containing G418 (800 mg/ml). G418-resistant clones were screened for expression of AML1/Evi-1 by Western blotting. For each construct, two independent clones with comparable expression were used in further studies. For the induction of granulocytic dierentiation, 32Dcl3 cells were washed twice with phosphate-buered saline and placed in RPMI 1640 medium supplemented with 10% FCS and 5 ng of recombinant human granulocyte colony stimulating factor (G-CSF) (Kirin Brewery) per ml, instead of murine IL-3. After 7 days, morphological studies were performed on cytospin preparations with WrightGiemsa staining.
RNA isolation and Northern analysis
Total cellular RNA was prepared according to the acid guanidium thiocyanate-phenol-chloroform method. Aliquots of 15 mg of the total RNA per lane were electrophoresed in 1.0% agarose gels and were transferred to nylon membranes (Hybond-N, Amersham Pharmacia Biotech). Membranes were prehybridized for 4 h at 428C. The probes for murine myeloperoxidase (MPO) or murine glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) were ampli®ed using reverse transcriptase-polymerase chain reaction (RT ± PCR) (Tanaka et al., 1995b) , and were labeled by a random primer method Oncogene Dominant negative inhibition on AML1 by AML1/Evi-1 and CtBP K Izutsu et al using the Megaprime DNA labeling system (Amersham Pharmacia Biotech) and [a- 32 P]dCTP (Amersham Pharmacia Biotech). The membranes were subjected to hybridization with the labeled probes at 428C overnight. Washed membranes were subjected to detection with autoradiography.
